Virus News and Research

Latest Virus News and Research

To avoid difficulties experienced during SARS epidemic, China must remain transparent in H7N9 efforts

"On this 10th anniversary of China's April 2003 admission that the SARS virus had spread across that country ... Beijing finds itself once again in a terrible position via-a-vis the microbial and geopolitical worlds," Laurie Garrett, a senior fellow for global health at the Council on Foreign Relations, writes in a Foreign Policy opinion piece, noting the emergence of a new strain of bird flu, H7N9, in the country.

25 Apr 2013

GPEI presents comprehensive six-year polio eradication plan at Global Vaccine Summit

Today, at the Global Vaccine Summit, the Global Polio Eradication Initiative presented a comprehensive six-year plan, the first plan to eradicate all types of polio disease – both wild poliovirus and vaccine-derived cases – simultaneously.

25 Apr 2013

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Vertex Pharmaceuticals Incorporated today announced new data from an interim analysis of the exploratory global Phase 3b CONCISE study evaluating the potential to shorten total treatment with telaprevir combination therapy to 12 weeks in certain people with genotype 1 chronic hepatitis C virus infection who have the IL28B CC genotype.

25 Apr 2013

Janssen submits Marketing Authorization Application to EMA for simeprevir approval

Medivir AB today announces that Janssen-Cilag International NV today has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval for simeprevir (TMC435).

25 Apr 2013

Sofosbuvir is safer than interferon for hepatitis C patients, say scientists

A new drug is offering dramatic cure rates for hepatitis C patients with two subtypes of the infection -- genotype 2 and 3, say a team of scientists led by Weill Cornell Medical College researchers.

25 Apr 2013

Targeted screening for chronic hepatitis C virus infection is cost-effective, say researchers

Researchers at the University of Cincinnati have found that targeted screening for populations with a higher estimated prevalence for hepatitis C may be cost-effective.

25 Apr 2013

Vesicular stomatitis virus spares non-cancerous cells and kills melanoma cells

Researchers from Yale University School of Medicine have demonstrated that vesicular stomatitis virus (VSV) is highly competent at finding, infecting, and killing human melanoma cells, both in vitro and in animal models, while having little propensity to infect non-cancerous cells.

25 Apr 2013

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia.

24 Apr 2013

WHO research team still unsure of H7N9 transmission routes

The WHO "has only a limited understanding of a deadly new form of avian flu that has killed 20 people and infected more than a hundred others, a team of researchers said on Monday, leaving unclear how the disease spreads and how virulent it could become," the Wall Street Journal reports.

24 Apr 2013

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals for the treatment of hepatitis C virus infection, continue to demonstrate high sustained viral response rates against genotype 1 HCV, across patient types.

24 Apr 2013

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection.

24 Apr 2013

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Janssen R&D Ireland today announced primary efficacy and safety results from two global Phase 3 studies demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naive genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when administered once daily with pegylated interferon and ribavirin.

24 Apr 2013

Home-based health education about diseases most effective, finds study

In the first study of its kind, lay health workers increased screening rates for hepatitis B virus (HBV) and knowledge about the disease among a group of Asian Americans, known as the Hmong, UC Davis researchers have found.

24 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

Animal models of Huntington's disease allow better insights into disease's genetics

Scientific progress in Huntington's disease (HD) relies upon the availability of appropriate animal models that enable insights into the disease's genetics and/or pathophysiology.

23 Apr 2013

World must be better prepared for potential pandemics

"In China an influenza virus never before seen in people had, as The Economist went to press, infected at least 82 and killed 17. Meanwhile a new type of coronavirus, the family that brought severe acute respiratory syndrome (SARS), is festering in the Middle East," an editorial in the magazine states.

23 Apr 2013

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Gilead Sciences, Inc. today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver in Amsterdam, The Netherlands.

23 Apr 2013

GeneCapture developing new device with one-hour pathogen testing capabilities

A company hatched as a partnership between The University of Alabama in Huntsville and chemical engineering professor Dr. Krishnan Chittur is in the design phase for a device that can provide physicians one-hour pathogen testing capabilities.

23 Apr 2013

Highly active ART does not appear to impair heart function, study suggests

Long-term use of highly active antiretroviral therapies does not appear to be associated with impaired heart function in children and adolescents in a study that sought to determine the cardiac effects of prolonged exposure to HAART on children infected with the human immunodeficiency virus, according to a report published Online First by JAMA Pediatrics, a JAMA Network publication.

23 Apr 2013

Number of H7N9 cases surpasses 100; U.S. CDC warns physicians to be vigilant

"The number of bird flu cases in China jumped Sunday to 102, including 20 deaths, the World Health Organization announced," CNN reports, noting 70 patients remain hospitalized with the new H7N9 avian flu strain and the "WHO said there is still no evidence of human-to-human transmission" (Gray/Armstrong, 4/22).

23 Apr 2013

Virus News and Research

Latest Virus News and Research

To avoid difficulties experienced during SARS epidemic, China must remain transparent in H7N9 efforts

GPEI presents comprehensive six-year polio eradication plan at Global Vaccine Summit

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Janssen submits Marketing Authorization Application to EMA for simeprevir approval

Sofosbuvir is safer than interferon for hepatitis C patients, say scientists

Targeted screening for chronic hepatitis C virus infection is cost-effective, say researchers

Vesicular stomatitis virus spares non-cancerous cells and kills melanoma cells

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

WHO research team still unsure of H7N9 transmission routes

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Home-based health education about diseases most effective, finds study

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Animal models of Huntington's disease allow better insights into disease's genetics

World must be better prepared for potential pandemics

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

GeneCapture developing new device with one-hour pathogen testing capabilities

Highly active ART does not appear to impair heart function, study suggests

Number of H7N9 cases surpasses 100; U.S. CDC warns physicians to be vigilant

A new way of characterising biomolecules eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Newsletters you may be interested in